Download PDF
Horm Metab Res 2020; 52(06): 347-356
DOI: 10.1055/a-1134-4980
Review

Hypokalemia and the Prevalence of Primary Aldosteronism

Sven Gruber
1   Klinik für Endokrinologie, Diabetologie und Klinische Ernährung, UniversitätsSpital Zürich, Zurich, Switzerland
,
Felix Beuschlein
1   Klinik für Endokrinologie, Diabetologie und Klinische Ernährung, UniversitätsSpital Zürich, Zurich, Switzerland
2   Medizinische Klinik und Poliklinik IV, Klinikum der Universität München, Munich, Germany
› Author Affiliations
› Further Information
Also available at
    Permissions and Reprints

Abstract

Hypokalemia is closely linked with the pathophysiology of primary aldosteronism (PA). Although hypokalemic PA is less common than the normokalemic course of the disease, hypokalemia is of particular importance for the manifestation and development of comorbidities. Specifically, a growing body of evidence demonstrates that hypokalemia in PA patients is associated with a more severe disease course regarding cardiovascular and metabolic morbidity and mortality. It is also well appreciated that low potassium levels per se can promote or exacerbate hypertension. The spectrum of hypokalemia-related symptoms ranges from asymptomatic courses to life-threatening conditions. Hypokalemia is found in 9–37% of all cases of PA with a predominance in patients with aldosterone producing adenoma. Conversely, hypokalemia resolves in almost 100% of cases after both, specific medical or surgical treatment of the disease. However, to date, high-level evidence about the prevalence of primary aldosteronism in a hypokalemic population is missing. Epidemiological data are expected from the recently launched IPAHK+study (“Incidence of Primary Aldosteronism in Patients with Hypokalemia”).

Key words

primary aldosteronism - hypokalemia - potassium - hypertension


Publication History

Received: 10 December 2019

Accepted: 02 March 2020

Article published online:
06 April 2020

© Georg Thieme Verlag KG
Stuttgart · New York

 

  • References

  • 1 Byrd JB, Turcu AF, Auchus RJ. Primary aldosteronism. Circulation 2018; 138: 823-835
    Google Scholar
  • 2 Funder JW. Primary aldosteronism. Hypertension 2019; 74: 458-466
    Google Scholar
  • 3 Hannemann A, Wallaschofski H. Prevalence of primary aldosteronism in patient’s cohorts and in population-based studies – A review of the current literature. Horm Metab Res 2012; 44: 157-162
    Google Scholar
  • 4 Hannemann A, Bidlingmaier M, Friedrich N. et al. Screening for primary aldosteronism in hypertensive subjects: Results from two German epidemiological studies. Eur J Endocrinol 2012; 167: 7-15
    Google Scholar
  • 5 Pillai PR, Griffith M, Schwarcz MD. et al. Primary aldosteronism: Cardiovascular risk, diagnosis, and management. Cardiol Rev 2020; 28: 84-91
    Google Scholar
  • 6 Milliez P, Girerd X, Plouin P-F. et al. Evidence for an increased rate of cardiovascular events in patients with primary aldosteronism. J Am Coll Cardiol 2005; 45: 1243-1248
    Google Scholar
  • 7 Wu X, Yu J, Tian H. Cardiovascular risk in primary aldosteronism: A systematic review and meta-analysis. Medicine 2019; 98: e15985
    Google Scholar
  • 8 Funder JW, Carey RM, Mantero F. et al. The management of primary aldosteronism: case detection, diagnosis, and treatment: An endocrine society clinical practice guideline. J Clin Endocrinol Metab 2016; 101: 1889-1916
    Google Scholar
  • 9 [Anonymous] Clinical study of adrenal incidentaloma in Korea FAU - Kim, Hee Young FAU - Kim, Sin Gon FAU - Lee, Kye Won FAU - Seo, Ji A FAU - Kim, Nan Hee FAU - Choi, Kyung Mook FAU - Baik, Sei Hyun FAU - Choi, Dong Seop. Korean J Intern Med 2005; 20: 303-309
    Google Scholar
  • 10 Conn JW. Presidential address: Part I. Painting background Part II. Primary aldosteronism, a new clinical syndrome. J Lab Clin Med 1955; 45: 3-17
    Google Scholar
  • 11 Conn JW, Louis LH. Primary aldosteronism: A new clinical entity. Trans Assoc Am Phys 1955; 68: 215
    Google Scholar
  • 12 Ganguly A. Primary aldosteronism. N Engl J Med 1998; 339: 1828-1834
    Google Scholar
  • 13 Kaplan NM. Hypokalemia in the hypertensive patient: With observations on the incidence of primary aldosteronism. Ann Inter Med 1967; 66: 1079-1090
    Google Scholar
  • 14 Gordon RD, Ziesak MD, Tunny TJ. et al. Evidence that primary aldosteronism may not be uncommon: 12% incidence among antihypertensive drug trial volunteers. Clin Exp Pharmacol Physiol 1993; 20: 296-298
    Google Scholar
  • 15 Mulatero P, Stowasser M, Loh K-C. et al. Increased diagnosis of primary aldosteronism, including surgically correctable forms, in centers from five continents. J Clin Endocrinol Metab 2004; 89: 1045-1050
    Google Scholar
  • 16 Gordon RD, Stowasser M, Tunny TJ. et al. High incidence of primary aldosteronism in 199 patients referred with hypertension. Clin Exp Pharmacol Physiol 1994; 21: 315-318
    Google Scholar
  • 17 Gallay BJ, Ahmad S, Xu L. et al. Screening for primary aldosteronism without discontinuing hypertensive medications: Plasma aldosterone-renin ratio. Am J Kidney Dis 2001; 37: 699-705
    Google Scholar
  • 18 Calhoun DA, Nishizaka MK, Zaman MA. et al. Hyperaldosteronism among black and white subjects with resistant hypertension. hypertension. 2002; 40: 892-896
    Google Scholar
  • 19 Acelajado MC, Calhoun DA. Aldosteronism and resistant hypertension. Int J Hypertens 2011; 2011: 837817
    Google Scholar
  • 20 Dudenbostel T, Calhoun DA. Resistant hypertension, obstructive sleep apnoea and aldosterone. J Hum Hypertens 2012; 26: 281-287
    Google Scholar
  • 21 Ekmekcioglu C, Elmadfa I, Meyer AL. et al. The role of dietary potassium in hypertension and diabetes. J Physiol Biochem 2016; 72: 93-106
    Google Scholar
  • 22 Vaidya A, Mulatero P, Baudrand R. et al. The expanding spectrum of primary aldosteronism: Implications for diagnosis, pathogenesis, and treatment. Endocr Rev 2018; 39: 1057-1088
    Google Scholar
  • 23 Zacchia M, Abategiovanni ML, Stratigis S. et al. Potassium: From physiology to clinical implications. Kidney Dis (Basel, Switzerland) 2016; 2: 72-79
    Google Scholar
  • 24 Gennari FJ. Hypokalemia. N Engl J Med 1998; 339: 451-458
    Google Scholar
  • 25 Clausen T, Everts ME. Regulation of the Na, K-pump in skeletal muscle. Kidney Int 1989; 35: 1-13
    Google Scholar
  • 26 Palmer BF. Regulation of potassium homeostasis. Clin J Am Soc Nephrol 2015; 10: 1050-1060
    Google Scholar
  • 27 Udensi UK, Tchounwou PB. Potassium homeostasis, oxidative stress, and human disease. Int J Clin Exp Physiol 2017; 4: 111-122
    Google Scholar
  • 28 Field MJ, Giebisch GJ. Hormonal control of renal potassium excretion. Kidney Int 1985; 27: 379-387
    Google Scholar
  • 29 Cannavo A, Bencivenga L, Liccardo D. et al. Aldosterone and mineralocorticoid receptor system in cardiovascular physiology and pathophysiology. Oxid Med Cell Longev. 2018 1204598.
    Google Scholar
  • 30 Atlas SA. The renin-angiotensin aldosterone system: Pathophysiological role and pharmacologic inhibition. J Manag Care Pharm 2007; 13 (8 Suppl B) 9-20
    Google Scholar
  • 31 Balakumar P, Anand-Srivastava MB, Jagadeesh G. Renin-angiotensin-aldosterone: An inclusive, an invigorative, an interactive and an interminable system. Pharmacol Res 2017; 125: 1-3
    Google Scholar
  • 32 Kawai T, Forrester SJ, O’Brien S. et al. AT1 receptor signaling pathways in the cardiovascular system. Pharmacol Res 2017; 125: 4-13
    Google Scholar
  • 33 Larsen PR, Kronenberg HM, Melmed S. et al. Williams textbook of endocrinology. Saunders; Philadelphia: 2003
    Google Scholar
  • 34 El Ghorayeb N, Bourdeau I, Lacroix A. Role of ACTH and other hormones in the regulation of aldosterone production in primary aldosteronism. Front Endocrinol 2016; 7: 72
    Google Scholar
  • 35 Shibata S, Rinehart J, Zhang J. et al. Mineralocorticoid receptor phosphorylation regulates ligand binding and renal response to volume depletion and hyperkalemia. Cell Metab 2013; 18: 660-671
    Google Scholar
  • 36 Arroyo JP, Ronzaud C, Lagnaz D. et al. Aldosterone paradox: Differential regulation of ion transport in distal. Nephron Physiology (Bethesda) 2011; 26: 115-123
    Google Scholar
  • 37 Choi M, Scholl UI, Yue P. et al. K+channel mutations in adrenal aldosterone-producing adenomas and hereditary hypertension. Science 2011; 331: 768-772
    Google Scholar
  • 38 Azizan EAB, Poulsen H, Tuluc P. et al. Somatic mutations in ATP1A1 and CACNA1D underlie a common subtype of adrenal hypertension. Nat Genet 2013; 45: 1055-1060
    Google Scholar
  • 39 Daniil G, Fernandes-Rosa FL, Chemin J. et al. CACNA1H mutations are associated with different forms of primary aldosteronism. EBioMedicine 2016; 13: 225-236
    Google Scholar
  • 40 Beuschlein F, Boulkroun S, Osswald A. et al. Somatic mutations in ATP1A1 and ATP2B3 lead to aldosterone-producing adenomas and secondary hypertension. Nat Genet 2013; 45: 440-444
    Google Scholar
  • 41 Fernandes-Rosa FL, Boulkroun S, Zennaro M-C. Somatic and inherited mutations in primary aldosteronism. J Mol Endocrinol 2017; 59: R47-R63
    Google Scholar
  • 42 Aburto NJ, Hanson S, Gutierrez H. et al. Effect of increased potassium intake on cardiovascular risk factors and disease: Systematic review and meta-analyses. BMJ (Clinical Research Ed) 2013; 346: f1378
    Google Scholar
  • 43 Kardalas E, Paschou SA, Anagnostis P. et al. Hypokalemia: A clinical update. Endocr Connect 2018; 7: R135-r146
    Google Scholar
  • 44 Paice BJ, Paterson KR, Onyanga-Omara F. et al. Record linkage study of hypokalaemia in hospitalized patients. Postgrad Med J 1986; 62: 187-191
    Google Scholar
  • 45 Marti G, Schwarz C, Leichtle AB. et al. Etiology and symptoms of severe hypokalemia in emergency department patients. Eur J Emerg Med 2014; 21: 46-51
    Google Scholar
  • 46 Chaker Ben S, Houssem H, Kamel B. Drug-induced hypokalaemia. Curr Drug Safety 2009; 4: 55-61
    Google Scholar
  • 47 Macdonald JE, Struthers AD. What is the optimal serum potassium level in cardiovascular patients?. J Am Coll Cardiol 2004; 43: 155-161
    Google Scholar
  • 48 Schulman M, Narins RG. Hypokalemia and cardiovascular disease. Am J Cardiol 1990; 65: E4-E9
    Google Scholar
  • 49 Tran TTT, Pease A, Wood AJ. et al. Review of evidence for adult diabetic ketoacidosis management protocols. Front Endocrinol 2017; 8: 106
    Google Scholar
  • 50 Schilbach K, Junnila RK, Bidlingmaier M. Aldosterone to renin ratio as screening tool in primary aldosteronism. Exp Clin Endocrinol Diabetes 2019; 127: 84-92
    Google Scholar
  • 51 Stowasser M, Ahmed AH, Pimenta E. et al. Factors affecting the aldosterone/renin ratio. Horm Metab Res 2012; 44: 170-176
    Google Scholar
  • 52 Brown JJ, Chinn RH, Davies DL. et al. Falsely high plasma potassium values in patients with hyperaldosteronism. Br Med J 1970; 2: 18-20
    Google Scholar
  • 53 Don BR, Sebastian A, Cheitlin M. et al. Pseudohyperkalemia caused by fist clenching during phlebotomy. N Engl J Med 1990; 322: 1290-1292
    Google Scholar
  • 54 Fischer E, Beuschlein F, Bidlingmaier M. et al. Commentary on the endocrine society practice guidelines: Consequences of adjustment of antihypertensive medication in screening of primary aldosteronism. Rev Endocr Metab Disord 2011; 12: 43-48
    Google Scholar
  • 55 Krogager ML, Torp-Pedersen C, Mortensen RN. et al. Short-term mortality risk of serum potassium levels in hypertension: A retrospective analysis of nationwide registry data. Eur Heart J 2016; 38: 104-112
    Google Scholar
  • 56 Krishna GG. Effect of potassium intake on blood pressure. J Am Soc Nephrol 1990; 1: 43-52
    Google Scholar
  • 57 Binia A, Jaeger J, Hu Y. et al. Daily potassium intake and sodium-to-potassium ratio in the reduction of blood pressure: A meta-analysis of randomized controlled trials. J Hypertens 2015; 33: 1509-1520
    Google Scholar
  • 58 Whelton PK, He J, Cutler JA. et al. Effects of oral potassium on blood pressure: Meta-analysis of randomized controlled clinical trials. JAMA 1997; 277: 1624-1632
    Google Scholar
  • 59 Oberleithner H, Callies C, Kusche-Vihrog K. et al. Potassium softens vascular endothelium and increases nitric oxide release. Proc Natl Acad Sci USA 2009; 106: 2829-2834
    Google Scholar
  • 60 Liu Z, Peng J, Lu F. et al. Salt loading and potassium supplementation: effects on ambulatory arterial stiffness index and endothelin-1 levels in normotensive and mild hypertensive patients. J Clin Hypertens (Greenwich) 2013; 15: 485-496
    Google Scholar
  • 61 Haddy FJ, Vanhoutte PM, Feletou M. Role of potassium in regulating blood flow and blood pressure. Am J Physiol Regul Integr Comp Physiol 2006; 290: R546-R552
    Google Scholar
  • 62 Terker AS, Zhang C, McCormick JA. et al. Potassium modulates electrolyte balance and blood pressure through effects on distal cell voltage and chloride. Cell Metab 2015; 21: 39-50
    Google Scholar
  • 63 Rengarajan S, Lee DH, Oh YT. et al. Increasing plasma [K+] by intravenous potassium infusion reduces NCC phosphorylation and drives kaliuresis and natriuresis. Am J Physiol Renal Physiol 2014; 306: F1059-F1068
    Google Scholar
  • 64 Rossi GP, Rossi E, Pavan E. et al. Screening for primary aldosteronism with a logistic multivariate discriminant analysis. Clin Endocrinol (Oxf) 1998; 49: 713-723
    Google Scholar
  • 65 Fogari R, Preti P, Zoppi A. et al. Prevalence of primary aldosteronism among unselected hypertensive patients: A prospective study based on the use of an aldosterone/renin ratio above 25 as a screening test. Hypertens Res 2007; 30: 111-117
    Google Scholar
  • 66 Monticone S, Burrello J, Tizzani D. et al. Prevalence and clinical manifestations of primary aldosteronism encountered in primary care practice. J Am Coll Cardiol 2017; 69: 1811-1820
    Google Scholar
  • 67 Rossi GP, Bernini G, Caliumi C. et al. A prospective study of the prevalence of primary aldosteronism in 1125 hypertensive patients. J Am Coll Cardiol 2006; 48: 2293-2300
    Google Scholar
  • 68 Käyser SC, Deinum J, de Grauw WJ. et al. Prevalence of primary aldosteronism in primary care: A cross-sectional study. Br J Gen Pract 2018; 68: e114-e122
    Google Scholar
  • 69 Ito Y, Takeda R, Takeda Y. Subclinical primary aldosteronism. Best Pract Res Clin Endocrinol Metab 2012; 26: 485-495
    Google Scholar
  • 70 Markou A, Pappa T, Kaltsas G. et al. Evidence of primary aldosteronism in a predominantly female cohort of normotensive individuals: A very high odds ratio for progression into arterial hypertension. J Clin Endocrinol Metab 2013; 98: 1409-1416
    Google Scholar
  • 71 Baudrand R, Guarda FJ, Fardella C. et al. Continuum of renin-independent aldosteronism in normotension. Hypertension (Dallas, Tex: 1979) 2017; 69: 950-956
    Google Scholar
  • 72 Schirpenbach C, Segmiller F, Diederich S. et al. The diagnosis and treatment of primary hyperaldosteronism in Germany: Results on 555 patients from the German Conn Registry. Dtsch Arztebl Int 2009; 106: 305-311
    Google Scholar
  • 73 Cohn JN, Kowey PR, Whelton PK. et al. New guidelines for potassium replacement in clinical practice: A contemporary review by the national council on potassium in clinical practice. Arch Inter Med 2000; 160: 2429-2436
    Google Scholar
  • 74 Crop MJ, Hoorn EJ, Lindemans J. et al. Hypokalaemia and subsequent hyperkalaemia in hospitalized patients. Nephrol Dial Transplant 2007; 22: 3471-3477
    Google Scholar
  • 75 Williams TA, Lenders JWM, Mulatero P. et al. Outcomes after adrenalectomy for unilateral primary aldosteronism: An international consensus on outcome measures and analysis of remission rates in an international cohort. Lancet Diabetes Endocrinol 2017; 5: 689-699
    Google Scholar
  • 76 Fischer E, Hanslik G, Pallauf A. et al. Prolonged zona glomerulosa insufficiency causing hyperkalemia in primary aldosteronism after adrenalectomy. J Clin Endocrinol Metab 2012; 97: 3965-3973
    Google Scholar
  • 77 Mattsson C, Young WF. Primary aldosteronism: Diagnostic and treatment strategies. Nat Clin Pract Nephrol 2006; 2: 198-208
    Google Scholar
  • 78 Karagiannis A, Tziomalos K, Papageorgiou A. et al. Spironolactone versus eplerenone for the treatment of idiopathic hyperaldosteronism. Exp Opin Pharmacother 2008; 9: 509-515
    Google Scholar
  • 79 Karashima S, Yoneda T, Kometani M. et al. Comparison of eplerenone and spironolactone for the treatment of primary aldosteronism. Hypertens Res 2015; 39
    Google Scholar
  • 80 Parthasarathy HK, Ménard J, White WB. et al. A double-blind, randomized study comparing the antihypertensive effect of eplerenone and spironolactone in patients with hypertension and evidence of primary aldosteronism. J Hypertens 2011; 29: 980-990
    Google Scholar